Formula I PDE2 Inhibitors for Brain Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PDE2 inhibitors face challenges due to poor metabolic stability and inability to cross the blood-brain barrier, limiting their effectiveness in treating PDE2-mediated disorders such as anxiety, depression, and cognitive impairment.
Innovation Solution
Development of novel compounds with potent and selective PDE2 inhibitory properties, specifically designed to improve oral availability and brain access, represented by compounds of Formula I, which inhibit PDE2-mediated hydrolysis of cGMP with an IC50 of less than 1 μM and exhibit improved biophysical and physiochemical properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing PDE2 inhibitors are used, then PDE2 activity is inhibited, but metabolic stability is poor and brain penetration is limited
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of PDE2 inhibitors through specific substituent patterns (R1-R6 groups) to improve metabolic stability while maintaining PDE2 inhibition efficacy. The compounds of Formula I are designed with optimized molecular properties including lipophilicity, molecular weight, and functional group composition to enhance both stability and brain penetration.
2Reliability
If existing PDE2 inhibitors are used, then PDE2 activity is inhibited, but ability to cross blood-brain barrier is poor
Solution Approach 1:
The patent optimizes brain penetration by adjusting key physicochemical parameters of the inhibitor molecules, including logP (lipophilicity), molecular weight, and hydrogen bonding capacity. The compounds of Formula I are designed to balance polarity and lipophilicity to facilitate blood-brain barrier crossing while maintaining target engagement.
3Ease of operation
If compounds are designed for improved brain penetration, then oral availability and brain access are enhanced, but molecular structure complexity increases
Solution Approach 1:
The patent applies local quality by introducing specific functional groups and substituent patterns at particular positions (R1-R6) of the core molecular structure. Each substituent is strategically placed to provide localized improvements in oral availability and brain penetration without requiring complete restructuring of the entire molecule.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds demonstrate enhanced brain penetration and therapeutic efficacy in treating PDE2-mediated disorders, including anxiety, depression, and cognitive impairment, by effectively increasing cGMP and cAMP levels, thereby improving cognitive function and memory.
Implementation Method 1
PDE2 inhibitory compounds of Formula I... inhibit PDE2-mediated hydrolysis of cGMP... PDE2 is a 105-KDa homodimer that is expressed in a wide variety of tissues and cell types including brain... PDE2 hydrolyzes both cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP)
Data Source
AI summary
The present disclosure relates to novel PDE2 inhibitory compounds of Formula I as described herein, their use as pharmaceuticals and pharmaceutical compositions comprising them.